Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Enanta Pharmaceuticals Inc

ENTA
Current price
10.63 USD -0.08 USD (-0.75%)
Last closed 10.71 USD
ISIN US29251M1062
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 241 761 920 USD
Yield for 12 month +7.70 %
1Y
3Y
5Y
10Y
15Y
ENTA
21.11.2021 - 28.11.2021

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts. Address: 500 Arsenal Street, Watertown, MA, United States, 02472

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

21 USD

P/E ratio

Dividend Yield

Current Year

+79 204 000 USD

Last Year

+86 160 000 USD

Current Quarter

+17 971 000 USD

Last Quarter

+17 054 000 USD

Current Year

+76 833 000 USD

Last Year

+83 187 000 USD

Current Quarter

+17 377 000 USD

Last Quarter

+16 433 000 USD

Key Figures ENTA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -120 341 000 USD
Operating Margin TTM -134.58 %
PE Ratio
Return On Assets TTM -17.18 %
PEG Ratio
Return On Equity TTM -59.64 %
Wall Street Target Price 21 USD
Revenue TTM 71 960 000 USD
Book Value 7.03 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -4.9 %
Dividend Yield
Gross Profit TTM 86 160 000 USD
Earnings per share -5.45 USD
Diluted Eps TTM -5.45 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY -66.2 %
Profit Margin -160.27 %

Dividend Analytics ENTA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ENTA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ENTA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.865
Price Sales TTM 3.3597
Enterprise Value EBITDA -0.291
Price Book MRQ 1.6235

Financials ENTA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ENTA

For 52 weeks

8.08 USD 17.8 USD
50 Day MA 12.35 USD
Shares Short Prior Month 2 910 550
200 Day MA 13.07 USD
Short Ratio 20.43
Shares Short 2 917 239
Short Percent 14.64 %